GNNS.F Stock Overview
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genscript Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.25 |
| 52 Week High | HK$2.44 |
| 52 Week Low | HK$1.05 |
| Beta | 1.08 |
| 1 Month Change | -9.15% |
| 3 Month Change | n/a |
| 1 Year Change | -52.83% |
| 3 Year Change | -72.53% |
| 5 Year Change | -45.89% |
| Change since IPO | 40.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNNS.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -2.4% |
| 1Y | -52.8% | -5.5% | 23.3% |
Return vs Industry: GNNS.F underperformed the US Life Sciences industry which returned -6.6% over the past year.
Return vs Market: GNNS.F underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| GNNS.F volatility | |
|---|---|
| GNNS.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNNS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GNNS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,284 | Weihui Shao | www.genscript.com |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation.
Genscript Biotech Corporation Fundamentals Summary
| GNNS.F fundamental statistics | |
|---|---|
| Market cap | US$2.69b |
| Earnings (TTM) | -US$177.01m |
| Revenue (TTM) | US$1.01b |
2.7x
P/S Ratio-15.2x
P/E RatioIs GNNS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNNS.F income statement (TTM) | |
|---|---|
| Revenue | US$1.01b |
| Cost of Revenue | US$468.10m |
| Gross Profit | US$541.49m |
| Other Expenses | US$718.50m |
| Earnings | -US$177.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 53.63% |
| Net Profit Margin | -17.53% |
| Debt/Equity Ratio | 48.1% |
How did GNNS.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 14:20 |
| End of Day Share Price | 2024/12/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genscript Biotech Corporation is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Linda Lu | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Yue-Kwong Lui | China Renaissance Securities |